Investment Management
Cowen Investment Management is the Investment Management division of Cowen. We aim to build on Cowen’s core insights by developing differentiated, actively managed strategies that seek to meet the dynamic needs of our clients
Cowen Investment Management delivers differentiated strategies to a diverse client base of sophisticated investors including institutions, corporations, pension plans, sovereign wealth funds, foundations and endowments, multi-family offices and high net worth individuals.
We seek to pursue strategies that are focused in areas in which Cowen has an existing knowledge base and aim to align with Cowen’s ESG mission. Directly and through its related advisors, we offer strategies in Healthcare and Life Sciences, Sustainable Investments, Healthcare Royalties, Merger Arbitrage, and Activism.
Cowen Investment Management is a signatory to the UN Principles of Responsible Investment (UNPRI).
Leading with Vision
Cowen Healthcare Investments (CHI) makes mid-to-late stage investments into innovative private biopharmaceutical and healthcare companies. Cowen began investing in this strategy in 2012.
Latest CHI News
CHI Portfolio
- Neuron23
- 2seventy bio
- Scipher Medicine
- Electra Therapeutics
- Anaveon
- Acelyrin, Inc.
- Lycia Therapeutics
- Obsidian Therapeutics
- Arch Oncology
- Omega Therapeutics
- Prometheus
- Neuron23™
- F2G
- Escient
- Freeline
- Nodthera
- Autobahn
- Keros Therapeutics
- Larimar Therapeutics
- Akouos
- VectivBio
- AM Pharma
- Cullinan Oncology
- Oncorus
- Repare Therapeutics
- Concentric Analgesics
- Inozyme Pharma
- KSQ
- Evox Therapeutics
- Therachon*
- Pliant Therapeutics
- Cadent Therapeutics
- Precision Biosciences
- Semma Therapeutics*
- Orchard Therapeutics
- Kezar Life Sciences
- Compass Therapeutics
- Livongo
- G1 Therapeutics
- True North Therapeutics*
- Audentes
- Corvus Pharmaceuticals
- Ovid Therapeutics
- Editas Medicine
- Unum Therapeutics*
- MykoKardia
- Aeglea Biotherapeutics
- KemPharma Inc
- Global Blood Therapeutics
- American Well
- Naurex Inc*
- Blueprint Medicine
- Avalanche Biotech*
- Ultra Genyx Pharmaceuticals
- Bluebirdbio
- GBT
*CHI Portfolio Companies with an asterisk have been acquired and/or experienced a name change; the link provided is directed to each company’s current website.
Founded in 2018, Cowen Sustainable Investments (CSI) provides tailored financing and data analytics solutions to companies that are accelerating the world’s transition to an environmentally sustainable economy by addressing pollution, waste, and resource constraints.
With a focus on companies of proven technologies and products that can be enhanced with data analytics resources as well as strong management teams, the investment themes pursued by CSI include clean transportation, sustainable food production, industrial efficiency as well as renewables and storage.
Ramius is a focused and fundamentally research-driven merger arbitrage strategy. The current Ramius merger arbitrage team has managed merger arbitrage strategies since 2011.
Starboard Value is a New York-based investment adviser with a focused and fundamental approach to investing in publicly-traded US companies. Starboard invests in deeply undervalued companies and actively engages with management teams and boards of directors to identify and execute on opportunities to unlock value for the benefit of all shareholders.
Starboard’s principals have managed investments in this manner since 2002.
Learn more about Starboard Value.
Founded in 2006, HealthCare Royalty Partners (HCR) is an investment firm that purchases royalties and uses debt-like structures to invest in commercial or near-commercial stage biopharmaceutical assets.
Learn more about HealthCare Royalty Partners.
Our team of dedicated investment professionals seek to capitalize on disruption and dislocation across market, geographies and sectors.
